En­do pays $658M in a fur­ther bet on col­la­gen-based med­i­cines, buy­ing out long­time bio­phar­ma part­ner

A lit­tle less than two years af­ter En­do Phar­ma­ceu­ti­cals’ deal to pur­chase Som­er­set Ther­a­peu­tics fell through, the Irish drug­mak­er is re­turn­ing to the well with a much big­ger ac­qui­si­tion.

En­do has agreed to buy BioSpecifics Tech­nolo­gies for a whop­ping $658 mil­lion, the two com­pa­nies an­nounced Mon­day, in the cul­mi­na­tion of a re­search agree­ment signed all the way back in 2004. En­do will pur­chase all of BioSpecifics’ out­stand­ing stock for about $540 mil­lion, valu­ing the com­pa­ny at $88.50 per share — a 45% pre­mi­um on the $61.02 share price at which the com­pa­ny closed on Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER